Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin

J. F. Gallegos-Orozco, A. Loaeza-del Castillo, A. P. Fuentes, M. García-Sandoval, L. Soto, R. Rodríguez, M. C. Gutiérrez-Ruíz, G. Gutiérrez-Reyes, A. Bonder, M. A. Olivera, David Kershenobich

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Interferon-based therapy induces changes in viral dynamics in chronic hepatitis C (CHC) patients. Aims: The aim of this study was to assess early hepatitis C virus (HCV)-RNA changes and evaluate its predictive value to achieve sustained viral response (SVR) in patients with CHC treated with peginterferon α-2b weekly plus ribavirin daily for 48 weeks. Methods: HCV-RNA was measured at baseline, 48 h, 4, 12, 24 and 48 weeks of treatment and 24 weeks after treatment. Results: Eighteen HCV genotype 1 patients were included (13 male, five female) with a mean age of 44.4 ± 11.9 years. Nine patients achieved SVR (50%). Viral decline occurred as early as 48 h; the magnitude of decline was statistically different between both groups (P <0.01). Responders had a ≥ 1 log10 drop in HCV-RNA at 48 h (positive predictive value (PPV) of 89% to achieve SVR) that persisted at week 4. By week 12, serum HCV-RNA was undetectable (PPV 100%). Conclusions: Our data indicate that peginterferon α-2b plus ribavirin treatment produces significant changes in HCV dynamics that can be detected as early as 48 h after the first dose of peginterferon α-2b and that these changes are useful in predicting response to therapy in CHC patients.

Original languageEnglish (US)
Pages (from-to)91-95
Number of pages5
JournalLiver International
Volume25
Issue number1
DOIs
StatePublished - Feb 2005

Fingerprint

Ribavirin
Chronic Hepatitis C
Hepacivirus
RNA
Therapeutics
Interferons
Genotype
Serum

Keywords

  • Early viral response
  • HCV
  • Peginterferon α-2b
  • Sustained viral response
  • Viral dynamics

ASJC Scopus subject areas

  • Hepatology

Cite this

Gallegos-Orozco, J. F., Loaeza-del Castillo, A., Fuentes, A. P., García-Sandoval, M., Soto, L., Rodríguez, R., ... Kershenobich, D. (2005). Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin. Liver International, 25(1), 91-95. https://doi.org/10.1111/j.1478-3231.2005.1040.x

Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin. / Gallegos-Orozco, J. F.; Loaeza-del Castillo, A.; Fuentes, A. P.; García-Sandoval, M.; Soto, L.; Rodríguez, R.; Gutiérrez-Ruíz, M. C.; Gutiérrez-Reyes, G.; Bonder, A.; Olivera, M. A.; Kershenobich, David.

In: Liver International, Vol. 25, No. 1, 02.2005, p. 91-95.

Research output: Contribution to journalArticle

Gallegos-Orozco, JF, Loaeza-del Castillo, A, Fuentes, AP, García-Sandoval, M, Soto, L, Rodríguez, R, Gutiérrez-Ruíz, MC, Gutiérrez-Reyes, G, Bonder, A, Olivera, MA & Kershenobich, D 2005, 'Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin', Liver International, vol. 25, no. 1, pp. 91-95. https://doi.org/10.1111/j.1478-3231.2005.1040.x
Gallegos-Orozco, J. F. ; Loaeza-del Castillo, A. ; Fuentes, A. P. ; García-Sandoval, M. ; Soto, L. ; Rodríguez, R. ; Gutiérrez-Ruíz, M. C. ; Gutiérrez-Reyes, G. ; Bonder, A. ; Olivera, M. A. ; Kershenobich, David. / Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin. In: Liver International. 2005 ; Vol. 25, No. 1. pp. 91-95.
@article{0212fa5c3df141ee849d3d1466ebcad1,
title = "Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin",
abstract = "Background: Interferon-based therapy induces changes in viral dynamics in chronic hepatitis C (CHC) patients. Aims: The aim of this study was to assess early hepatitis C virus (HCV)-RNA changes and evaluate its predictive value to achieve sustained viral response (SVR) in patients with CHC treated with peginterferon α-2b weekly plus ribavirin daily for 48 weeks. Methods: HCV-RNA was measured at baseline, 48 h, 4, 12, 24 and 48 weeks of treatment and 24 weeks after treatment. Results: Eighteen HCV genotype 1 patients were included (13 male, five female) with a mean age of 44.4 ± 11.9 years. Nine patients achieved SVR (50{\%}). Viral decline occurred as early as 48 h; the magnitude of decline was statistically different between both groups (P <0.01). Responders had a ≥ 1 log10 drop in HCV-RNA at 48 h (positive predictive value (PPV) of 89{\%} to achieve SVR) that persisted at week 4. By week 12, serum HCV-RNA was undetectable (PPV 100{\%}). Conclusions: Our data indicate that peginterferon α-2b plus ribavirin treatment produces significant changes in HCV dynamics that can be detected as early as 48 h after the first dose of peginterferon α-2b and that these changes are useful in predicting response to therapy in CHC patients.",
keywords = "Early viral response, HCV, Peginterferon α-2b, Sustained viral response, Viral dynamics",
author = "Gallegos-Orozco, {J. F.} and {Loaeza-del Castillo}, A. and Fuentes, {A. P.} and M. Garc{\'i}a-Sandoval and L. Soto and R. Rodr{\'i}guez and Guti{\'e}rrez-Ru{\'i}z, {M. C.} and G. Guti{\'e}rrez-Reyes and A. Bonder and Olivera, {M. A.} and David Kershenobich",
year = "2005",
month = "2",
doi = "10.1111/j.1478-3231.2005.1040.x",
language = "English (US)",
volume = "25",
pages = "91--95",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin

AU - Gallegos-Orozco, J. F.

AU - Loaeza-del Castillo, A.

AU - Fuentes, A. P.

AU - García-Sandoval, M.

AU - Soto, L.

AU - Rodríguez, R.

AU - Gutiérrez-Ruíz, M. C.

AU - Gutiérrez-Reyes, G.

AU - Bonder, A.

AU - Olivera, M. A.

AU - Kershenobich, David

PY - 2005/2

Y1 - 2005/2

N2 - Background: Interferon-based therapy induces changes in viral dynamics in chronic hepatitis C (CHC) patients. Aims: The aim of this study was to assess early hepatitis C virus (HCV)-RNA changes and evaluate its predictive value to achieve sustained viral response (SVR) in patients with CHC treated with peginterferon α-2b weekly plus ribavirin daily for 48 weeks. Methods: HCV-RNA was measured at baseline, 48 h, 4, 12, 24 and 48 weeks of treatment and 24 weeks after treatment. Results: Eighteen HCV genotype 1 patients were included (13 male, five female) with a mean age of 44.4 ± 11.9 years. Nine patients achieved SVR (50%). Viral decline occurred as early as 48 h; the magnitude of decline was statistically different between both groups (P <0.01). Responders had a ≥ 1 log10 drop in HCV-RNA at 48 h (positive predictive value (PPV) of 89% to achieve SVR) that persisted at week 4. By week 12, serum HCV-RNA was undetectable (PPV 100%). Conclusions: Our data indicate that peginterferon α-2b plus ribavirin treatment produces significant changes in HCV dynamics that can be detected as early as 48 h after the first dose of peginterferon α-2b and that these changes are useful in predicting response to therapy in CHC patients.

AB - Background: Interferon-based therapy induces changes in viral dynamics in chronic hepatitis C (CHC) patients. Aims: The aim of this study was to assess early hepatitis C virus (HCV)-RNA changes and evaluate its predictive value to achieve sustained viral response (SVR) in patients with CHC treated with peginterferon α-2b weekly plus ribavirin daily for 48 weeks. Methods: HCV-RNA was measured at baseline, 48 h, 4, 12, 24 and 48 weeks of treatment and 24 weeks after treatment. Results: Eighteen HCV genotype 1 patients were included (13 male, five female) with a mean age of 44.4 ± 11.9 years. Nine patients achieved SVR (50%). Viral decline occurred as early as 48 h; the magnitude of decline was statistically different between both groups (P <0.01). Responders had a ≥ 1 log10 drop in HCV-RNA at 48 h (positive predictive value (PPV) of 89% to achieve SVR) that persisted at week 4. By week 12, serum HCV-RNA was undetectable (PPV 100%). Conclusions: Our data indicate that peginterferon α-2b plus ribavirin treatment produces significant changes in HCV dynamics that can be detected as early as 48 h after the first dose of peginterferon α-2b and that these changes are useful in predicting response to therapy in CHC patients.

KW - Early viral response

KW - HCV

KW - Peginterferon α-2b

KW - Sustained viral response

KW - Viral dynamics

UR - http://www.scopus.com/inward/record.url?scp=20044364746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044364746&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2005.1040.x

DO - 10.1111/j.1478-3231.2005.1040.x

M3 - Article

C2 - 15698404

AN - SCOPUS:20044364746

VL - 25

SP - 91

EP - 95

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 1

ER -